FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to new long-acting co-agonists of glucagon and GLP-1 receptors; it can be used in medicine. The invention discloses peptide capable of interaction with both a glucagon receptor and GLP-1 receptor, wherein such a peptide is conjugated with fatty organic acids and/or polyethylene glycol (PEG) by a number of positions of an amino acid sequence.
EFFECT: invention can be used in medical practice in the treatment of diseases related to metabolism disorders, for example in the treatment of diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or obesity.
28 cl, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ACYLATED DOUBLE AGONISTS OF GLP-1/GLP-2 | 2017 |
|
RU2753193C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2015 |
|
RU2736637C2 |
| TREATMENT OF NEUROLOGICAL DISEASES | 2017 |
|
RU2755997C2 |
| PEGILATED BIOLOGICALLY ACTIVE PEPTIDES AND THEIR APPLICATION | 2017 |
|
RU2748576C2 |
| MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | 2020 |
|
RU2816492C2 |
| LONG-ACTING DOUBLE AGONIST OF GLUCAGON-LIKE PEPTIDE-1 AND GLUCAGON RECEPTORS | 2021 |
|
RU2799327C1 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| IMPROVED PEPTIDE DRUGS FOR TREATMENT OF NASH AND OTHER DISORDERS | 2019 |
|
RU2790209C2 |
| KV1_3 BLOCKERS | 2020 |
|
RU2825633C1 |
